glp 1 clinical studies You might know them as Ozempic, Wegovy, Mounjaro, and Zepbound. GLP-1 receptor agonists are best known for managing diabetes and promoting weight loss, but researchers are discovering a wide spectrum of effective The GLP-1 Clinical Trial Landscape

National estimates of glucagon-like peptide-1 (GLP-1) use in Australia have revealed approximately half a million people are regularly using these medicines, and almost half of this group are paying between $200-$700 out-of-pocket to access them for conditions other than diabetes

GLP-1RAs may also be a therapeutic target for asthma as animal models show that these drugs reduce allergen-induced airway inflammation, as the GLP-1R is expressed on lung epithelial and endothelial cells

A randomized controlled trial published in the New England Journal of Medicine demonstrated that tesamorelin significantly reduced visceral adipose tissue in patients with abdominal fat accumulation (Falutz et al., 2007)

Stem Cell Rev and Rep

Several research teams have targeted GSH synthesis inhibitors as potential therapeutic agents